IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
An i mal Health:
Novartis An i mal Health de vel ops and mar kets para siti cides and med i cines for farm and do mes tic an i mals,
as well as in sect and ro dent con trol prod ucts. Main prod ucts for com pan ion an i mals in clude treat ment for
atopic der ma ti tis, in tes ti nal par a sites and heartworm con trol, heart fail ure and re nal in suf fi ciency and
vet er i nary su ture lines. For farm an i mals, the unit mar kets farm fly and par a site con trol prod ucts,
therapeutic anti-infectives, and vaccines.
The com pany is ranked num ber six in the An i mal Health in dus try, ac cord ing to Novartis in 2008. In 2008
growth was driven by the com pan ion an i mal busi ness as the world cri sis in farm ing damp ened growth in
this mar ket. Sankyo Lifetech ac qui si tion in Ja pan, closed in 2007, strength ened Novartis pres ence in
com pan ion-an i mal segment.
CIBA Vi sion:
The CIBA Vi sion unit mar kets a range of con tact lenses and lens care prod ucts in more than 70 coun tries.
R&D ef forts have pro duced lenses such as O2OPTIX, high-ox y gen, breath able lenses; Night & Day,
high-ox y gen ex tended wear lenses that can be worn for up to 30 con tin u ous nights; and Fo cus Dai lies,
daily dis pos able lenses for help pro vide the clear est, most com fort able vi sion pos si ble. In lens care, CIBA
Vi sion’s prod ucts in clude AQuify Multi-Pur pose So lu tion/Solo Care Aqua All-In-One So lu tion and Clear
Care/Aosept Plus per ox ide sys tem. Ac cord ing to Novartis it was sec ond in the world in this area in 2008.
Growth in the year bene fited from new con tact lenses in the US and other key markets.
Mis cel la neous
Vac cines
Novartis Vac cines is the world’s fifth-larg est vac cines busi ness and the world’s sec ond-larg est man u fac -
turer of flu vac cines and has im por tant meningococcal, pe di at ric and travel vac cine fran chises. The com -
pany’s port fo lio of prod ucts in cludes vac cines for in flu enza, men in gi tis, ra bies, tick-borne en ceph a li tis
(TBE), Haemophilus influenzae B (Hib), po lio, mumps, mea sles and ru bella and diph the ria, tet a nus and
per tus sis (whoop ing cough). The vac cines busi ness was in cor po rated in 2006 with the ac qui si tion of
Chiron. The busi ness di vi sion con sists of two units: vac cines and blood test ing busi ness, which re tains the
Chiron name, ded i cated to pre vent ing the spread of infectious diseases through novel blood-screening
tools.
In 2008, Vac cines & Di ag nos tics net sales rose 21.1% to $1.8 bil lion, driven by de liv er ies of the H5N1
pan demic in flu enza vac cines to the US gov ern ment, sales of com po nents for pe di at ric vac cines and
steady growth in di ag nos tics. There were, how ever, lower US sea sonal in flu enza vaccine sales.
A ma jor prod uct in this sec tor is the Fluvirin in flu enza vac cine. Novartis was the first com pany to com -
mer cially pro duce and mar ket cell cul ture-based vac cines to pre vent in flu enza. The OptaFlu vac cine,
based on novel cell cul ture tech nol ogy in stead of tra di tional egg-based pro duc tion, was ap proved in Eu -
rope in 2007. Cell-cul ture based in flu enza vac cines prom ise many ad van tages over egg-based pro duc -
tion, in clud ing greater re li abil ity and re duced pro duc tion lead time that could be crit i cal in a pan demic.
This tech nol ogy is con sid ered the most im por tant pro duc tion in no va tion for in flu enza vac cines in over 50
years. In the USA phase III trials were ongoing in early 2009.
In 2007, Novartis also re ceived EU ap proval for Focetria, a vac cine for use in a pan demic in flu enza out -
break. Focetria will be man u fac tured to con tain strains de clared at the time of a pan demic by the World
Health Or ga ni za tion (WHO). It will also in clude the pro pri etary Novartis adjuvant MF59, which could ex -
tend sup plies by al low ing for small amounts of vi ral an ti gens to be used in each dose com pared to vac -
© 2009 IMS Health In cor po rated or its af fil i ates Page 72